325 related articles for article (PubMed ID: 27554034)
1. Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration.
Essex RW; Nguyen V; Walton R; Arnold JJ; McAllister IL; Guymer RH; Morlet N; Young S; Barthelmes D; Gillies MC;
Ophthalmology; 2016 Nov; 123(11):2393-2400. PubMed ID: 27554034
[TBL] [Abstract][Full Text] [Related]
2. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration.
Arnold JJ; Campain A; Barthelmes D; Simpson JM; Guymer RH; Hunyor AP; McAllister IL; Essex RW; Morlet N; Gillies MC;
Ophthalmology; 2015 Jun; 122(6):1212-9. PubMed ID: 25846847
[TBL] [Abstract][Full Text] [Related]
3. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
[TBL] [Abstract][Full Text] [Related]
4. An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration.
Berg K; Roald AB; Navaratnam J; Bragadóttir R
Acta Ophthalmol; 2017 Dec; 95(8):796-802. PubMed ID: 28926190
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Poor Visual Outcomes of Neovascular Age-related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
Nguyen CL; Gillies MC; Nguyen V; Daien V; Cohn A; Banerjee G; Arnold J;
Ophthalmology; 2019 May; 126(5):735-742. PubMed ID: 30529685
[TBL] [Abstract][Full Text] [Related]
6. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN.
Rahimy E; Rayess N; Ho AC; Regillo CD
Retina; 2016 May; 36(5):875-80. PubMed ID: 26630316
[TBL] [Abstract][Full Text] [Related]
7. TWO YEAR OUTCOMES OF "TREAT AND EXTEND" INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Barthelmes D; Nguyen V; Daien V; Campain A; Walton R; Guymer R; Morlet N; Hunyor AP; Essex RW; Arnold JJ; Gillies MC;
Retina; 2018 Jan; 38(1):20-28. PubMed ID: 28145976
[TBL] [Abstract][Full Text] [Related]
8. Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab.
Gillies MC; Campain A; Walton R; Simpson JM; Arnold JJ; Guymer RH; McAllister IL; Hunyor AP; Essex RW; Morlet N; Barthelmes D;
Ophthalmology; 2015 Mar; 122(3):589-594.e1. PubMed ID: 25458197
[TBL] [Abstract][Full Text] [Related]
9. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
Kvannli L; Krohn J
Acta Ophthalmol; 2017 Nov; 95(7):678-682. PubMed ID: 28139082
[TBL] [Abstract][Full Text] [Related]
10. Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes.
Ciulla TA; Hussain RM; Pollack JS; Williams DF
Ophthalmol Retina; 2020 Jan; 4(1):19-30. PubMed ID: 31324588
[TBL] [Abstract][Full Text] [Related]
11. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration.
Barthelmes D; Campain A; Nguyen P; Arnold JJ; McAllister IL; Simpson JM; Hunyor AP; Guymer R; Essex RW; Morlet N; Gillies MC;
Br J Ophthalmol; 2016 Dec; 100(12):1640-1645. PubMed ID: 26994110
[TBL] [Abstract][Full Text] [Related]
12. Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Anti-VEGF Injections Using a Treat-Extend-Stop Protocol.
Adrean SD; Chaili S; Ramkumar H; Pirouz A; Grant S
Ophthalmology; 2018 Jul; 125(7):1047-1053. PubMed ID: 29439828
[TBL] [Abstract][Full Text] [Related]
13. Real-world treatment outcomes of neovascular Age-related Macular Degeneration in the Netherlands.
Verbraak FD; Ponsioen DL; Tigchelaar-Besling OAM; Nguyen V; Gillies MC; Barthelmes D; Klaver CCW
Acta Ophthalmol; 2021 Sep; 99(6):e884-e892. PubMed ID: 33354933
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
Peden MC; Suñer IJ; Hammer ME; Grizzard WS
Ophthalmology; 2015 Apr; 122(4):803-8. PubMed ID: 25596618
[TBL] [Abstract][Full Text] [Related]
15. Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents.
Evans RN; Reeves BC; Maguire MG; Martin DF; Muldrew A; Peto T; Rogers C; Chakravarthy U
JAMA Ophthalmol; 2020 Oct; 138(10):1043-1051. PubMed ID: 32816002
[TBL] [Abstract][Full Text] [Related]
16. Recurrence Rate of Choroidal Neovascularization in Neovascular Age-Related Macular Degeneration Managed with a Treat-Extend-Stop Protocol.
Adrean SD; Chaili S; Grant S; Pirouz A
Ophthalmol Retina; 2018 Mar; 2(3):225-230. PubMed ID: 31047590
[TBL] [Abstract][Full Text] [Related]
17. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
Johnston RL; Carius HJ; Skelly A; Ferreira A; Milnes F; Mitchell P
Adv Ther; 2017 Mar; 34(3):703-712. PubMed ID: 28144918
[TBL] [Abstract][Full Text] [Related]
18. Early and Late Retinal Pigment Epithelium Tears after Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration.
Invernizzi A; Nguyen V; Arnold J; Young S; Barthelmes D; Gillies MC
Ophthalmology; 2018 Feb; 125(2):237-244. PubMed ID: 28993010
[TBL] [Abstract][Full Text] [Related]
19. Projection of Long-Term Visual Acuity Outcomes Based on Initial Treatment Response in Neovascular Age-Related Macular Degeneration.
Nguyen V; Daien V; Guymer R; Young S; Hunyor A; Fraser-Bell S; Hunt A; Gillies MC; Barthelmes D;
Ophthalmology; 2019 Jan; 126(1):64-74. PubMed ID: 30149035
[TBL] [Abstract][Full Text] [Related]
20. Recurrent Neovascular Age-Related Macular Degeneration after Discontinuation of Vascular Endothelial Growth Factor Inhibitors Managed in a Treat-and-Extend Regimen.
Aslanis S; Amrén U; Lindberg C; Epstein D
Ophthalmol Retina; 2022 Jan; 6(1):15-20. PubMed ID: 33775926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
